IGM Biosciences Inc
NASDAQ:IGMS

Watchlist Manager
IGM Biosciences Inc Logo
IGM Biosciences Inc
NASDAQ:IGMS
Watchlist
Price: 1.27 USD -2.31% Market Closed
Market Cap: 76.6m USD

Net Margin

-36.5%
Current
Improving
by 10 382.5%
vs 3-y average of -10 419%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-36.5%
=
Net Income
$-53m
/
Revenue
$145.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-36.5%
=
Net Income
$-53m
/
Revenue
$145.1m

Peer Comparison

Country Company Market Cap Net
Margin
US
IGM Biosciences Inc
NASDAQ:IGMS
76.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
181.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
157.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 79% of companies in the United States of America
Percentile
21th
Based on 15 072 companies
21th percentile
-36.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

IGM Biosciences Inc
Glance View

Market Cap
76.6m USD
Industry
Biotechnology

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGMS Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-36.5%
=
Net Income
$-53m
/
Revenue
$145.1m
What is IGM Biosciences Inc's current Net Margin?

The current Net Margin for IGM Biosciences Inc is -36.5%, which is above its 3-year median of -10 419%.

How has Net Margin changed over time?

Over the last 3 years, IGM Biosciences Inc’s Net Margin has increased from -55 483.8% to -36.5%. During this period, it reached a low of -55 483.8% on May 30, 2022 and a high of -36.5% on Jul 30, 2025.

Back to Top